检索范围:
排序: 展示方式:
Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA
《环境科学与工程前沿(英文)》 2011年 第5卷 第3期 页码 409-416 doi: 10.1007/s11783-011-0349-8
关键词: cadmium hapten monoclonal antibody enzyme-linked immunosorbent assay (ELISA)
Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang
《医学前沿(英文)》 2019年 第13卷 第1期 页码 83-93 doi: 10.1007/s11684-019-0682-z
Colorectal cancer (CRC) is a common malignant tumor in the digestive tract, and 30%–85% of CRCs express epidermal growth factor receptors (EGFRs). Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC have been demonstrated to cause an S492R mutation in EGFR. However, little is known about the biological function of S492R EGFR. Therefore, we attempted to elucidate its biological function in CRC cells and explore new treatment strategies for this mutant form. Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR. Furthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependent cellular cytotoxicity effect on CRC cells bearing S492R EGFR than mAb C225. mAb CH12 obviously suppressed the growth of CRC xenografts with S492R EGFR mutations in vivo. Thus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR mutation.
关键词: S492R EGFR ectodomain mutation colorectal cancer mAb CH12 immunnotherapy
Passive antibody therapy in emerging infectious diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1021-y
关键词: SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies
From SARS to MERS: evidence and speculation
null
《医学前沿(英文)》 2016年 第10卷 第4期 页码 377-382 doi: 10.1007/s11684-016-0466-7
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic pathogen. In 2012, the infectious outbreak caused by MERS-CoV in Saudi Arabia has spread to more than 1600 patients in 26 countries, resulting in over 600 deaths. Without a travel history, few clinical and radiological features can reliably differentiate MERS from SARS. But in real world, comparing with SARS, MERS presents more vaguely defined epidemiology, more severe symptoms, and higher case fatality rate. In this review, we summarize the recent findings in the field of MERS-CoV, especially its molecular virology, interspecies mechanisms, clinical features, antiviral therapies, and the further investigation into this disease. As a newly emerging virus, many questions are not fully answered, including the exact mode of transmission chain, geographical distribution, and animal origins. Furthermore, a new protocol needs to be launched to rapidly evaluate the effects of unproven antiviral drugs and vaccine to fasten the clinical application of new drugs.
关键词: middle east respiratory syndrome animal origin cross-species transmission monoclonal antibody
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
《医学前沿(英文)》 2021年 第15卷 第4期 页码 644-648 doi: 10.1007/s11684-021-0847-4
关键词: neutralizing antibody antibody cocktail SARS-CoV-2 COVID-19 therapeutic strategy
单克隆抗体治疗过敏性疾病的研究现状 Review
陈彦, 王炜, 袁慧慧, 李艳, 吕喆, 崔烨, 刘杰, 孙英
《工程(英文)》 2021年 第7卷 第11期 页码 1552-1556 doi: 10.1016/j.eng.2020.06.029
过敏性疾病是常见的慢性疾病之一,由变应原在不同器官上引发变态反应,在临床上以不同器官的疾病为主要表现形式,如哮喘、特应性皮炎、鼻-鼻窦炎等,常累及儿童和成人。由于其在世界范围内的广泛流行和对患者生活质量的影响,采用新型生物疗法治疗过敏性疾病的研究业已成为该领域的热点。已知多种因素可促进或触发Th2 型免疫应答,导致2 型细胞因子和免疫球蛋白E(IgE)的产生并参与过敏性疾病的发生发展,因此,开发针对2 型细胞因子和IgE 的单克隆抗体为治疗过敏性疾病提供了新的策略。此外,一些潜在的靶点,如上皮源性预警素-胸腺基质淋巴细胞生成素(TSLP)和白介素33(IL-33)业已进入临床研究阶段。这些新的和潜在的靶点极大地提高了变应性疾病的治疗机会。本文阐述了目前已开发的针对细胞因子、细胞因子受体和IgE 的单克隆抗体在过敏性疾病治疗中的作用,并对这些抗体的临床效果进行了讨论和分析。
Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,
《医学前沿(英文)》 2009年 第3卷 第3期 页码 277-283 doi: 10.1007/s11684-009-0047-0
关键词: hepatitis B virus gene variation hepatitis B surface antigen immune escape enzyme-linked immunosorbent assay
王蔚芳,李青梅,柴书军,甘玲玲,洪磊,郭军庆,雷霁霖
《中国工程科学》 2014年 第16卷 第9期 页码 16-20
应用细胞工程技术研制大菱鲆免疫球蛋白M(immunoglobulin M,IgM)的单克隆抗体并分析其免疫学特性。小鼠骨髓瘤细胞NS0 与经IgM免疫的BALB/C小鼠脾细胞融合,经过反复有限稀释法克隆,筛选获得4 株抗大菱鲆IgM的单克隆抗体杂交瘤细胞株,分别为B1D1、D5C2、E1B2 和F4A1。经小鼠腹水扩大生产后,单抗效价为1∶1.024×106检测灵敏度为32 ng/mL。Western blot 分析表明,获得的单抗与IgM 重链区特异性结合。交叉结果显示,单抗与大菱鲆血清呈强阳性反应,与褐牙鲆、红鳍东方鲀、许氏平鲉、六线鱼、鲈鱼均呈微弱阳性反应,而与半滑舌鳎、鲤鱼、鲫鱼、草鱼、鳙鱼的血清无交叉反应。本研究制备的大菱鲆IgM单克隆抗体效价高、灵敏度高、特异性强,适合用于大菱鲆免疫学相关研究和生产实际应用。
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 340-349 doi: 10.1007/s11684-017-0565-0
Benralizumab is a monoclonal antibody that targets interleukin-5 receptor α to deplete blood eosinophils and improve the clinical outcomes of allergic asthma. We conducted a meta-analysis to evaluate the safety and efficacy of different doses of benralizumab in patients with eosinophilic asthma. All randomized controlled trials involving benralizumab treatment for patients with eosinophilic asthma, which were searched in PubMed, Embase, and the Cochrane Library published until January 2017, as well as the rate of asthmatic exacerbation, pulmonary functionality, asthma control, quality of life scores, and adverse events were included. Randomized-effect models were used in the meta-analysis to calculate the pooled mean difference, relative risks, and 95% confidence intervals. Five studies involving 1951 patients were identified. Compared with the placebo, benralizumab treatment demonstrated significant improvements in the forced expiratory volume in 1?s (FEV1), Asthma Quality of Life Questionnaire scores, decreased asthmatic exacerbation and Asthma Control Questionnaire-6 (ACQ-6) scores. Benralizumab treatment was also not associated with increased adverse events. These findings indicated that benralizumab can be safely used to improve FEV1, enhance patient symptom control and quality of life, and reduce the risk of exacerbations and ACQ-6 scores in patients with eosinophilic asthma. Furthermore, our meta-analysis showed that benralizumab with 30 mg (every eight weeks) dosage can improve the health-related quality of life and appear to be more effective than 30 mg (every four weeks) dosage. Overall, data indicated that the optimal dosing regimen for benralizumab was possibly 30 mg (every eight weeks).
关键词: benralizumab anti-interleukin-5 monoclonal antibody eosinophilic asthma meta-analysis
High-level expression of recombinant IgG1 by CHO K1 platform
Ningning Xu, Jianfa Ou, Al-Karim (Al) Gilani, Lufang Zhou, Margaret Liu
《化学科学与工程前沿(英文)》 2015年 第9卷 第3期 页码 376-380 doi: 10.1007/s11705-015-1531-5
关键词: Chinese hamster ovary (CHO) monoclonal antibody IgG1 amplification cell line development
Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,
《工程(英文)》 doi: 10.1016/j.eng.2023.09.012
关键词: Poly- N -acetylglucosamine Conjugate vaccine Monoclonal antibody
Human monoclonal antibodies as candidate therapeutics against emerging viruses
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 462-470 doi: 10.1007/s11684-017-0596-6
The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
关键词: human monoclonal antibodies emerging infectious diseases SARS-CoV MERS-CoV Ebola virus
《医学前沿(英文)》 doi: 10.1007/s11684-023-0996-8
Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT
《化学科学与工程前沿(英文)》 2012年 第6卷 第2期 页码 216-223 doi: 10.1007/s11705-012-1289-y
关键词: recombinant protein polyclonal antibody label-free biosensor impedance white spot syndrome virus (WSSV)
null
《医学前沿(英文)》 2016年 第10卷 第2期 页码 204-211 doi: 10.1007/s11684-016-0443-1
CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionally involved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cells to endothelial cells and hepatocytes, respectively. CD176 could be a promising target for antitumor immunotherapy. We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage display library. A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from this library. The CD176 scFv was expressed in Escherichia coli and purified. The purified scFv can bind to the natural CD176 expressed on the surface of cancer cells. Furthermore, the CD176 scFv inhibits the adhesion of CD176+ cancer cells to endothelial cells and hepatocytes. This CD176 scFv provides a basis for future development of recombinant CD176-specific antibodies that can be used in therapeutic application.
关键词: CD176 Thomsen-Friedenreich antigen scFv cancer therapy adhesion metastasis
标题 作者 时间 类型 操作
Preparation of hapten-specific monoclonal antibody for cadmium and its ELISA application to aqueous samples
Huan HE, Bo TANG, Cheng SUN, Shaogui YANG, Weijuan ZHENG, Zichun HUA
期刊论文
Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12
Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang
期刊论文
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
期刊论文
Preparation, identification, and clinical application of anti-HBs monoclonal antibody that binds both
Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,
期刊论文
Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials
null
期刊论文
High-level expression of recombinant IgG1 by CHO K1 platform
Ningning Xu, Jianfa Ou, Al-Karim (Al) Gilani, Lufang Zhou, Margaret Liu
期刊论文
Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial Pathogens Producing β-1–6-Linked Poly-N-Acetylglucosamine (PNAG)
Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,
期刊论文
BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation
期刊论文
Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv
Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT
期刊论文